The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

Journal of HIV-AIDS & Social Services is a pivotal academic platform committed to advancing the understanding and management of HIV-AIDS through the lens of social services. Published by Routledge Journals, Taylor & Francis Ltd, this journal spans significant years from 2002 to 2024, making it a key resource for the latest research and practices in the intersecting fields of health and social sciences. With an ISSN of 1538-1501 and an E-ISSN of 1538-151X, the journal holds a respectable position within the academic community, marked by its categorization in the Q3 quartile of both Health (Social Science) and Infectious Diseases as of 2023. The journal strives to provide a forum for innovative research addressing the complexities of HIV-AIDS, incorporating perspectives from various stakeholders, including healthcare providers, policymakers, and community organizations. Although it currently does not offer open access options, its indexed presence and dedicated readership ensure the dissemination of vital knowledge in a field that is more critical than ever. For researchers, professionals, and students dedicated to combating HIV-AIDS, this journal serves not just as a publication, but as a catalyst for change in global health initiatives.

AIDS AND BEHAVIOR, published by SPRINGER/PLENUM PUBLISHERS, is a leading scholarly journal dedicated to the interdisciplinary study of HIV/AIDS, focusing particularly on the behavioral aspects of the epidemic. With an impressive impact factor reflected in its Q1 rankings across key categories including Infectious Diseases, Public Health, and Social Psychology, this journal serves as a vital resource for researchers, clinicians, and public health professionals. It encompasses a wide scope of research, from the psychosocial factors influencing HIV transmission to innovative interventions that promote safe practices. Although it does not offer open access, the journal's rigorous peer-review process ensures the dissemination of high-quality, impactful research. Covering data from 1997 to 2024, AIDS AND BEHAVIOR is positioned at the forefront of advancements in the field, making it an essential addition to any academic library and a must-read for those involved in combating HIV/AIDS.

LEPROSY REVIEW is a distinguished academic journal published by LEPRA in the United Kingdom, dedicated to advancing the understanding of leprosy and related infectious diseases. Since its inception, the journal has been a pivotal platform for disseminating research findings, clinical insights, and reviews in the fields of Dermatology, Infectious Diseases, and broader Medical Science. With an established history spanning from 1945 to the present, it has been categorized in the Q3 quartile for several subjects as per the latest 2023 rankings, indicating its valuable contributions to the scientific community. Although not an Open Access publication, LEPROSY REVIEW offers an important forum for researchers, healthcare professionals, and students to explore the nuances of leprosy research and treatment. Its impact in fostering academic dialogue around neglected tropical diseases is underscored by its rankings in Scopus, making it an essential resource for anyone invested in the fight against leprosy and enhancing the quality of life for affected populations.

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

Turk Dermatoloji Dergisi-Turkish Journal of Dermatology, published by Wolters Kluwer Medknow Publications, is a prominent platform dedicated to advancing the field of dermatology in Turkey and beyond. With an ISSN of 1307-7635 and an E-ISSN of 1308-5255, this journal plays a vital role in disseminating contemporary research and clinical advancements within the domain. While it is positioned in the Q4 quartile of dermatology journals, its contributions are essential for academics, medical practitioners, and students averse to the latest trends and breakthroughs in skin health. The journal assures accessibility to a broad audience, fostering knowledge exchange, collaboration, and innovation. Given its unique perspective rooted in Turkish dermatological practices, the Turkish Journal of Dermatology serves as a significant resource for enhancing professional competence and driving forward the science of dermatology through its vivid discussions and case studies. For researchers seeking a dedicated venue to publish their work or for professionals eager to stay informed, this journal is an indispensable resource in the ever-evolving landscape of dermatology.

Therapeutic Advances in Infectious Disease is a distinguished journal published by SAGE Publications Ltd, dedicated to advancing knowledge in the vital field of infectious diseases and pharmacology. With an impactful Open Access model since 2019, the journal facilitates unrestricted access to a wealth of high-quality research, enabling researchers, clinicians, and educators to stay at the forefront of infectious disease management and treatment. As a recognition of its contribution to the scientific community, the journal holds a prestigious Q1 quartile ranking in both Infectious Diseases and Medical Pharmacology as of 2023, underscoring its influence and relevance in these domains. The journal is positioned favorably within the Scopus rankings, with an impressive standing in the diverse categories of Medicine, emphasizing its commitment to disseminating innovative research. Through a rigorous peer-review process and a broad scope that covers therapeutic advancements, Therapeutic Advances in Infectious Disease serves as an essential resource for anyone involved in combating infectious diseases, offering insights that drive clinical applications and enhance patient care.

AIDS, published by Lippincott Williams & Wilkins, stands as a premier journal within the fields of immunology and infectious diseases, reflecting a distinguished history since its inception in 1987 and offering insights that shape contemporary research and practice. With an impressive impact factor and categorized in the Q1 quartile across critical areas including Immunology, Infectious Diseases, and Immunology and Allergy, the journal showcases high-quality, peer-reviewed articles that consistently contribute to the advancement of knowledge and innovation in the fight against AIDS and related conditions. Researchers and professionals will find its content invaluable, as it brings forth groundbreaking studies, novel therapeutic approaches, and comprehensive reviews that inform both clinical practices and public health policies. Although not an open access journal, it remains a vital resource for those committed to addressing one of the most pressing global health challenges of our time.

Dermatologica Sinica, published by Wolters Kluwer Medknow Publications, is an esteemed open-access journal in the field of dermatology that has been disseminating critical research since its inception in 2005. With an E-ISSN of 2223-330X and an ISSN of 1027-8117, this journal presents a platform for researchers, clinicians, and students to share cutting-edge findings and advancements in dermatological science. As of 2023, it proudly ranks in the Q2 category of dermatology journals and holds a notable position at rank #62 out of 142 in the Scopus Medicine - Dermatology category, placing it in the 56th percentile for impact. The journal transitioned to an open-access model in 2016, enhancing accessibility and visibility for groundbreaking studies worldwide. With a commitment to fostering innovation in the dermatological community, Dermatologica Sinica aims to advance the understanding and treatment of skin diseases while encouraging scholarly dialogue among practitioners and researchers across the globe.